Markelle Fultz
TOR
GAge 28Last season rank n/a
Turnovers per game — 25-26, league-wide. Lower is better.
League Leader0.2
This Player0.8
League Average1.3
Ranking Trend
Lower rank is better.
Full data
| Season | Rank |
|---|---|
| 17-18 | #349 |
| 18-19 | #325 |
| 19-20 | #164 |
| 20-21 | n/a |
| 21-22 | #193 |
| 22-23 | #87 |
| 23-24 | #260 |
| 24-25 | n/a |
| 25-26 | n/a |
Stat Trend
Track role, durability, and category growth by season. Scoring: 9-category
PTS
Full data
| Season | PTS |
|---|---|
| 17-18 | 7.1 |
| 18-19 | 8.2 |
| 19-20 | 12.1 |
| 20-21 | 12.9 |
| 21-22 | 10.8 |
| 22-23 | 14 |
| 23-24 | 7.8 |
| 24-25 | 2.9 |
| 25-26 | 0.8 |
Within-Season Trend
PTS by month across 25-26 (averages). Useful for spotting injury recovery and rookie/second-year ramps. Change the stat with the selector above.
Fantasy playoffs (final ~3 weeks)
Full data
| Month | PTS |
|---|---|
| Mar 2026 | 0.8 |
Fantasy playoffs run the final ~3 weeks of the season (late March into April); shown approximately at month resolution and dependent on your league's settings. ESPN and Yahoo defaults differ by about a week.
Depth Chart
Depth Chart
TOR — all five positions, best player first at each spot.
C
—
PF
—
SF
—
SG
—
PG
Markelle Fultz
Season History
9-categoryNBA profile
| SeasonNBA season | AgeAge during the season | TeamTeam | GPGames played | GSGames started | MPGMinutes per game | RankOverall fantasy rank (averages) | ValueFantasy ranking value (averages) | PTSPoints per game | REBRebounds per game | ASTAssists per game | STLSteals per game | BLKBlocks per game | 3PMThree-pointers made per game | FG%Field goal percentage | FGAField goal attempts per game | FT%Free throw percentage | FTAFree throw attempts per game | TOTurnovers per game |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25-26 | 28 | TOR | 5 | 0 | 7.2 | n/a | n/a | 0.8 | 0.2 | 1.6 | 0.4 | 0 | 0 | 18.2% | 2.2 | 0.0% | 0 | 0.8 |
| 24-25 | 27 | SAC | 21 | 0 | 8.8 | n/a | n/a | 2.9 | 1 | 1.3 | 0.5 | 0.1 | 0.2 | 41.8% | 3.2 | 100.0% | 0 | 0.7 |
| 23-24 | 26 | ORL | 43 | 0 | 21.2 | #260 | -1.74 | 7.8 | 3.2 | 2.8 | 1 | 0.3 | 0.1 | 47.2% | 7.6 | 69.7% | 0.8 | 1.2 |
| 22-23 | 25 | ORL | 60 | 0 | 29.6 | #87 | 3.08 | 14 | 3.9 | 5.7 | 1.5 | 0.4 | 0.5 | 51.4% | 11.3 | 78.3% | 2.4 | 2.3 |
| 21-22 | 24 | ORL | 18 | 0 | 20 | #193 | 0.03 | 10.8 | 2.7 | 5.5 | 1.1 | 0.3 | 0.2 | 47.4% | 9.7 | 80.6% | 1.7 | 2.2 |
| 20-21 | 23 | ORL | 8 | 0 | 26.9 | n/a | n/a | 12.9 | 3.1 | 5.4 | 1 | 0.3 | 0.5 | 39.4% | 13 | 89.5% | 2.4 | 2.3 |
| 19-20 | 22 | ORL | 72 | 0 | 27.7 | #164 | 0.59 | 12.1 | 3.3 | 5.1 | 1.3 | 0.2 | 0.5 | 46.5% | 10.7 | 73.0% | 2.2 | 2 |
| 18-19 | 21 | ORL | 19 | 0 | 22.5 | #325 | -3.21 | 8.2 | 3.7 | 3.1 | 0.9 | 0.3 | 0.2 | 41.9% | 8.2 | 56.8% | 1.9 | 1.3 |
| 17-18 | 20 | PHI | 14 | 0 | 18.1 | #349 | -3.72 | 7.1 | 3.1 | 3.8 | 0.9 | 0.3 | 0 | 40.5% | 7.9 | 47.6% | 1.5 | 1.2 |